secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001558370-25-001435
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Neurosciences doses first patients in Phase 1b PRECISE-AD trial of PMN310 for Alzheimer's disease
--------------------------------------------------------------------------------

- First patients dosed in Phase 1b PRECISE-AD trial evaluating PMN310, a humanized mAb targeting toxic Aβ oligomers.
- Interim six-month results expected in 1H 2026; topline results anticipated in 2H 2026.
- PMN310 selectively targets soluble amyloid-beta oligomers, avoiding monomers and plaques, potentially differentiating from current AD therapies.
- Rapid enrollment underscores unmet need for better AD treatments; investigators note need for effective and well-tolerated options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000155837025001435/0001558370-25-001435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000155837025001435/pmn-20250225x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-001435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer